Thursday, 25 July 2024

Gilead’s Biktarvy sustains viral suppression and tolerability in Asian HIV patients

16 October 2020 | News

Clinical study findings in Asian women and adult population living with HIV were presented at 2020 Asia Pacific Aids & Co-Infections Conference

Photo Credit: pexels

Photo Credit: pexels

Gilead Sciences, Inc. on 15 Oct 2020 announced findings from multiple studies in Asian population that evaluated the safety and efficacy of switching to once-daily, single tablet regimen, Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) from baseline regimens at the 2020 Asia Pacific AIDS & Co-Infections Conference (APACC).

A post-hoc pooled analysis from three studies demonstrated efficacy of switching to B/F/TAF from integrase strand transfer inhibitor (INSTI) based antiretroviral therapy, or a boosted protease inhibitor (PI) with two Nucleotide Reverse Transcriptase Inhibitors (NRTIs) baseline regimens, among virologically-suppressed Asian adults living with HIV. In the analysis, 100 percent of the 63 Asian adults who switched to B/F/TAF maintained virologic suppression (defined as HIV-1 RNA <50 copies/mL) with no emergent resistance, vs 95.9 percent (70/73) in those stay on baseline regimen (SBR) group, through a maximum of 48 weeks. B/F/TAF was well tolerated with no adverse events leading to discontinuation among Asian participants in the studies.

Similarly, an open-label, randomized, phase 3 study of women with HIV who were virologically suppressed (HIV-1 RNA < 50 copies/mL) on a baseline regimen (elvitegravir (E)/cobicistat (C)/F/TAF, E/C/F/tenofovir disoproxil fumarate (TDF), or atazanavir + ritonavir + F/TDF), found that virologic suppression was maintained in 100 percent of the subgroup of Asian women participants (n=48) vs 98 percent in the SBR group (53/54). B/F/TAF was well tolerated with no adverse events leading to discontinuation.

These results further demonstrate the well-established efficacy and safety profile of Biktarvy. No participant on B/F/TAF developed treatment-emergent resistance.  The additional data will further define the treatment regimen.

Biktarvy® (bictegravir 50mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg; B/F/TAF) is approved in Hong Kong, Singapore, South Korea, Taiwan and Thailand as a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection in adults.  B/F/TAF is indicated for the treatment of HIV-1 infection in adults without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account